Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific share transactions by Mr. W C Louv on April 26, 2012:
- Exercise of options over 2,684 ADSs granted on December 3, 2002, at $37.25 per ADS, followed by a sale at $46.132 per ADS.
- Exercise of options over 22,316 ADSs granted on December 3, 2002, at $37.25 per ADS, followed by a sale at $46.123 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Mr. W C Louv exercised and sold a total of 25,000 ADSs on April 26, 2012.
- The transactions were executed at a price significantly higher than the original grant price of $37.25 per ADS.
- The company was advised of these transactions on April 27, 2012.
- This filing does not contain quarterly or annual financial results.